Yuanhua Orthobotix (骨圣元化机器人), a Shenzhen-headquartered company making orthopedic surgical robot, recently received approval from China’s top drug administrator to market its surgical robot system catering to hip and knee operations, the first of its kind developed by a domestic company.
The certificate, which was granted by National Medical Products Administration, was the first such license obtained by Yuanhua Orthobotix since August 2022, when the startup was recognized as a state-level “AI medical equipment innovation pioneer.”
The surgical robot, named “Kunwu,” passed the test on safety and efficacy after it completed 166 operations at multiple clinical centers. The results proved that the device is able to help surgeons implant artificial knees or hips into the patient’s body with higher accuracy, while also improving the overall safety of the procedures, Yuanhua said in an official statement.
After landing the certification, Yuanhua’s “Kunwu” can be used to assist in surgeries on knee and hip joints, making it the first indigenously designed 2-in-1 surgical robot able to help replace knee and hip joints.
Yuanhua Orthobotix, founded in 2018, which comes with self-developed navigation technologies, software system and core components, is committed to assisting doctors in performing procedures such as knee, hip and ankle joint implant and also for the treatment of spinal injury and bone fracture.
The firm, a Series B startup, counts Sequoia China, Shenzhen Capital Group, CICC, Stone VC and Oriental Fortune Capital among its financial backers.
